Oncology News Burst from FDA: Durvalumab

From the Society for Immunotherapy of Cancer

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On February 16, 2018, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca Inc.) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Approval was based on a planned interim analysis of progression-free survival (PFS) from PACIFIC (NCT02125461), a randomized double-blind, placebo-controlled trial conducted in 713 patients with unresectable, stage III NSCLC. Patients completed concurrent platinum-based chemotherapy and radiation within 42 days prior to study drug initiation and had WHO performance status of 0 or 1. The major efficacy measures were PFS (blinded independent central review per RECIST 1.1) and overall survival (OS). With approximately 81% of planned events for the final analysis, the trial demonstrated a statistically significant improvement in PFS for durvalumab compared to placebo (HR 0.52; 95% CI: 0.42, 0.65; p<0.00010). The estimated median PFS was 16.8 months for patients receiving durvalumab and 5.6 months for those receiving placebo. Survival results were immature at the interim PFS analysis.

The most common adverse reactions (occurring in at least 20% of patients receiving durvalumab in PACIFIC) were cough, fatigue, pneumonitis/radiation pneumonitis, upper respiratory tract infections, dyspnea and rash.

The recommended dose and schedule for durvalumab for this indication is 10 mg/kg as an intravenous infusion over 60 minutes every two weeks.

Full prescribing information is available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761069s002lbl.pdf.

FDA granted this application Priority Review and Breakthrough Therapy designations. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics, available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).